Professor of Dermatology, University Pennsylvania
Dermatology
Dr. Alain H. Rook, MD
|
|
Give Review
Doctor Alain H. Rook, MD works in the field of Dermatology. He researched medicine at University of Michigan Medical School. He received awards:"Philadelphia Magazine", "America's Top Doctors", "America's Top Doctors for Cancer", "CMS Meaningful Use Stage 1 Certification", "Fellow (FAAD)" and "Super Doctor". Alain H. Rook is a published doctor and has 80 publications published. The lastest was: 'Genomic analysis of mycosis fungoides and Szary syndrome identifies recurrent alterations in TNFR2.' He accepts Medicare payments and is listed with Medicare.gov.
Publications
- Genomic analysis of mycosis fungoides and Sézary syndrome identifies recurrent alterations in TNFR2.
- Topical resiquimod can induce disease regression, eradicate malignant T Cells and enhance T Cell effector functions in cutaneous T Cell lymphoma.
- Improved pruritus correlates with lower levels of IL-31 in CTCL patients under different therapeutic modalities.
- Merkel Cell polyomavirus in low levels in folliculotropic mycosis fungoides represents a passenger, not a driver.
- Role of (18)F-fluorodeoxyglucose positron emission tomography imaging in the management of primary cutaneous lymphomas.
- Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: A report of 5 cases from the Southern Network on Adverse Reactions (SONAR) proj...
- Toll receptor agonist therapy of skin cancer and cutaneous T-Cell lymphoma.
- CD164 and FCRL3 Are Highly Expressed on CD4+CD26- T Cells in Sézary Syndrome Patients.
- Interleukin-31 Is Produced by the Malignant T-Cell Population in Cutaneous T-Cell Lymphoma and Correlates with CTCL Pruritus.
- Improvement in peripheral blood disease burden in patients with Sézary syndrome and leukemic mycosis fungoides after total Skin electron beam therapy.
- Clinically meaningful reduction in pruritus in patients with cutaneous T-Cell lymphoma treated with romidepsin.
- Topical chemotherapy in cutaneous T-Cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechloret...
- Romidepsin and interferon gamma: a novel combination for refractory cutaneous T-Cell lymphoma.
- Allogeneic hematopoietic SCT for primary cutaneous T Cell lymphomas.
- The beauty of TLR agonists for CTCL.
- Chronic Acyclovir-Resistant HSV-2 Ulcer in an Immunosuppressed Patient Treated With Topical Cidofovir.
- The relevance of photopheresis to autoreactive diseases.
- Inhibition of Cell-mediated immunity by the histone deacetylase inhibitor vorinostat: Implications for therapy of cutaneous T-Cell lymphoma.
- Peripheral blood findings in erythrodermic patients: importance for the differential diagnosis of Sézary syndrome.
- Congestive heart failure in a patient with cutaneous T-Cell lymphoma treated with low-dose interferon alfa-2b.
- High Clinical Response Rate of Sezary Syndrome to Immunomodulatory Therapies: Prognostic Markers of Response.
- Psoralen plus ultraviolet A light may be associated with clearing of peripheral blood disease in advanced cutaneous T-Cell lymphoma.
- Multicenter phase II trial of enzastaurin in patients with relapsed or refractory advanced cutaneous T-Cell lymphoma.
- Validity assessment of the cutaneous T-Cell lymphoma severity index to predict prognosis in advanced mycosis fungoides/Sézary syndrome.
- Sézary syndrome: immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC).
- Simultaneous Inhibition of mTOR-Containing Complex 1 (mTORC1) and MNK Induces Apoptosis of Cutaneous T-Cell Lymphoma (CTCL) Cells.
- Increased programmed death-1 expression on CD4+ T Cells in cutaneous T-Cell lymphoma: implications for immune suppression.
- Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-Cell lymphoma.
- A phase II placebo-controlled study of photodynamic therapy with topical hypericin and visible light irradiation in the treatment of cutaneous T-Cell lymphoma and psor...
- Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-Cell lymphoma.
- Primary cutaneous aggressive epidermotropic CD8+ T-Cell lymphoma.
- Extracorporeal photopheresis: past, present, and future.
- Vorinostat for the treatment of bullous pemphigoid in the setting of advanced, refractory cutaneous T-Cell lymphoma.
- A novel regimen of vorinostat with interferon gamma for refractory Sézary syndrome.
- In vivo imaging of cutaneous T-Cell lymphoma migration to the skin.
- Update on treatment of cutaneous T-Cell lymphoma.
- Clinical and in vitro resistance to bexarotene in adult T-Cell leukemia: loss of RXR-alpha receptor.
- Gamma c-signaling cytokines induce a regulatory T Cell phenotype in malignant CD4+ T lymphocytes.
- CD8+ epidermotropic cytotoxic T-Cell lymphoma with peripheral blood and central nervous system involvement.
- Lethal vascular leak syndrome after denileukin diftitox administration to a patient with cutaneous gamma/delta T-Cell lymphoma and occult cirrhosis.
- Resistance to FasL and tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in Sezary syndrome T-Cells associated with impaired death receptor an...
- Total Skin electron beam therapy may be associated with improvement of peripheral blood disease in Sézary syndrome.
- Stem Cell transplantation in advanced cutaneous T-Cell lymphoma.
- Differential effects of interleukin-2 and interleukin-15 versus interleukin-21 on CD4+ cutaneous T-Cell lymphoma Cells.
- IL-21 enhances antitumor responses without stimulating proliferation of malignant T Cells of patients with Sézary syndrome.
- Progressive multifocal leukoencephalopathy from JC virus in a patient with advanced mycosis fungoides.
- Bexarotene blunts malignant T-Cell chemotaxis in Sezary syndrome: reduction of chemokine receptor 4-positive lymphocytes and decreased chemotaxis to thymus and activat...
- Synthetic imidazoquinolines potently and broadly activate the Cellular immune response of patients with cutaneous T-Cell lymphoma: synergy with interferon-gamma enhanc...
- Apoptotic responses to all-trans retinoic acid of targretin-resistant, malignant, CD4+ peripheral blood T Cells from patients with Sezary syndrome.
- A phase II open-label study of recombinant human interleukin-12 in patients with stage IA, IB, or IIA mycosis fungoides.
- High clinical response rate with multimodality immunomodulatory therapy for Sézary syndrome.
- Mycosis fungoides and sezary syndrome: an update.
- Quantitative PCR on 5 genes reliably identifies CTCL patients with 5% to 99% circulating tumor Cells with 90% accuracy.
- Posttransplantation lymphoproliferative disease with features of lymphomatoid granulomatosis in a lung transplant patient.
- A role for regulatory T Cells in cutaneous T-Cell lymphoma; induction of a CD4 + CD25 + Foxp3+ T-Cell phenotype associated with HTLV-1 infection.
- CD8+ lymphoma in a patient with human immunodeficiency virus.
- The addition of interferon gamma to oral bexarotene therapy with photopheresis for Sézary syndrome.
- Association of change in clinical status and change in the percentage of the CD4+CD26- lymphocyte population in patients with Sézary syndrome.
- Immunopathogenesis and therapy of cutaneous T Cell lymphoma.
- Biological effects of bexarotene in cutaneous T-Cell lymphoma.
- Low-dose bexarotene and low-dose interferon alfa-2b for adult T-Cell leukemia/lymphoma associated with human T-lymphotropic virus 1.
- Impaired CD40L signaling is a cause of defective IL-12 and TNF-alpha production in Sézary syndrome: circumvention by hexameric soluble CD40L.
- Enhancement of the host immune responses in cutaneous T-Cell lymphoma by CpG oligodeoxynucleotides and IL-15.
- Low-dose oral bexarotene in combination with low-dose interferon alfa in the treatment of cutaneous T-Cell lymphoma: clinical synergism and possible immunologic mechan...
- Cytokine therapy of cutaneous T-Cell lymphoma: interferons, interleukin-12, and interleukin-2.
- Eosinophilic fasciitis and eosinophilic Cellulitis in a patient with abnormal circulating clonal T Cells: increased production of interleukin 5 and inhibition by inter...
- Complete remission in advanced blastic NK-Cell lymphoma/leukemia in elderly patients using the hyper-CVAD regimen.
- Extracorporeal photopheresis and multimodality immunomodulatory therapy in the treatment of cutaneous T-Cell lymphoma.
- Classification and prediction of survival in patients with the leukemic phase of cutaneous T Cell lymphoma.
- Psoralen plus long-wave UV-A (PUVA) and bexarotene therapy: An effective and synergistic combined adjunct to therapy for patients with advanced cutaneous T-Cell lymphoma.
- Extracorporeal photopheresis in the treatment of persistent rejection in a pediatric lung transplant recipient.
- Novel multimodality biologic response modifier therapy, including bexarotene and long-wave ultraviolet A for a patient with refractory stage IVa cutaneous T-Cell lymph...
- Sézary syndrome patients demonstrate a defect in dendritic Cell populations: effects of CD40 ligand and treatment with GM-CSF on dendritic Cell numbers an...
- Assessment of tumor burden and treatment response by 18F-fluorodeoxyglucose injection and positron emission tomography in patients with cutaneous T- and B-Cell lymphomas.
- Treatment of stage IA cutaneous T-Cell lymphoma with topical application of the immune response modifier imiquimod.
- Treatment of cutaneous T-Cell lymphoma with combined immunomodulatory therapy: a 14-year experience at a single institution.
- Denileukin diftitox for the treatment of panniculitic lymphoma.
- Synergistic enhancement of Cell-mediated immunity by interleukin-12 plus interleukin-2: basis for therapy of cutaneous T Cell lymphoma.
- Cytokines and other biologic agents as immunotherapeutics for cutaneous T-Cell lymphoma.
Schools
University Of Michigan Medical School
McGill University
University Penn
NihNiaid
Procedures Preformed
- Destruction of Benign Skin Lesion
- Destruction of Malignant Skin Lesion
Conditions Treated
- Acne
- Actinic Keratosis
- Athlete's Foot
- Atopic Dermatitis (Eczema)
- View All
Doctors Specialties
- Nephrology
- Dermatology
Accepted Insurances
Awards
- Philadelphia Magazine
- America's Top Doctors
- America's Top Doctors for Cancer
- CMS Meaningful Use Stage 1 Certification
- Fellow (FAAD)
- Super Doctor
Education
-
University of Pennsylvania Health System -
University of Michigan Medical School
Hospital
-
Hospital of the University of Pennsylvania -
Penn Presbyterian Medical Center -
Pennsylvania Hospital
Drug Facts
| NPI NUMBER | 1760417372 | |
| NPPES Provider LastName | ROOK | |
| NPPES Provider FirstName | ALAIN | |
| NPPES Provider ZIPCode | 191044306 | |
| NPPES Provider State | PA | |
| Specialty Description | Dermatology | |
| Total Claim Count | 407.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1760417372 |
| Last Name Of The Provider | ROOK |
| First Name Of The Provider | ALAIN |
| View All |
Similar Doctors
|
|
Dr. Jason M. Schoenfeld, MD |
|
|
Dr. Theodora K. Bernardini, DO |
|
|
Dr. Sidney M. Kobrin, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ellen J. Kim, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Aniruddha V. Palya, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Albert C. Yan, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Steven M. Brunelli, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kristin Cam, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Alan Wasserstein, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Joel D. Glickman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Joseph F. Sobanko, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kenneth E. Wasserman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nicholas L. Compton, MD |